DDInter1158 DDInter821
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity. Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases. Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of genetic disorders.
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Mesalazine {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Mesalazine {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) is bound by {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Mesalazine {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Givosiran
Mesalazine {u} (Compound) resembles {v} (Compound) Methyldopa
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Brentuximab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Mesalazine {u} (Compound) causes {v} (Side Effect) Hepatic necrosis
Hepatic necrosis {u} (Side Effect) is caused by {v} (Compound) Flucytosine
Flucytosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Givosiran
Mesalazine {u} (Compound) causes {v} (Side Effect) Hepatic necrosis
Hepatic necrosis {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Givosiran
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Mesalazine (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Mesalazine (Compound) binds MPO (Gene) and MPO (Gene) is bound by Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Mesalazine (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Givosiran
Mesalazine (Compound) resembles Methyldopa (Compound) and Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Mesalazine (Compound) causes Hepatic necrosis (Side Effect) and Hepatic necrosis (Side Effect) is caused by Flucytosine (Compound) and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Mesalazine (Compound) causes Hepatic necrosis (Side Effect) and Hepatic necrosis (Side Effect) is caused by Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Givosiran